Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Sep 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 03 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
- 03 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.